Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Avidex: T cells to therapeutics

Avidex: T cells to therapeutics

Similar to companies trying to use soluble forms of antigen-specific B cell receptors - a.k.a. antibodies - as therapeutics, Avidex Ltd. is trying to employ the T cell receptor as a therapeutic. The company has recently made the final technology advance that it believes was required to make TCRs therapeutically feasible, by increasing their affinity to

Read the full 613 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers